Saturday, October 12, 2024 7:46:27 PM
What is ELITE's future revenue potential???
Adderall IR...........$389.8 M
Adderall XR...........$1.56 B
Dantrolene............$6.3 M
Isradipine............$5.5 M
Loxapine..............$5 M
Phendimetrazine.......$4.5 M
Trimipramine..........$2 M
Naltrexone............$16 M
Phentermine Capsules..$7.5 M
Phentermine Tablets...$40 M
Vigabatrin............$233.7 M
Methotrexate..........$63.4M
Current on the market total = $2.334B
Many have not reached full market potential but based on the totals, Elite has approximately 2.5% of the total market for all the above based on FY2024 revenue.
Expect trending UP to over 5% for these in next couple of years = $116.7M
Percocet..............$500 M
Norco.................$477 M
Methadone.............$30 M
Launching SOON market total = $1.007B
Apply the same 2.5% and it will bring Elite an additional $25M in revenue.
Expect trending UP to over 5% for these in next several years = $50.4M in revenue.
Vyvanse...............$5.10 B
Expected approval in November 2024 at the latest and Elite say launch to take priority and as quick as possible.
Apply the same 2.5% and it will bring Elite an additional $127.5M in revenue.
OxyContin.............$720 M
Pending approval and resolving patent case.
Apply the same 2.5% and it will bring Elite an additional $18M in revenue.
So, just estimating revenue growth in FY2025 and following trend same increase from last year you will get $78M for current drugs and then add in those launching and it should be between $90M to $100M.
Now go out two years with currently manufactured drug sales increasing, launched drugs taking off, Vyvanse and Oxy in production and Elite could be generating over $200 MILLION in revenue!!! The above does not include Israel/Dexcel's sales of Adderall, does not include other possibilities with Dexcel, does not include Elite's current development of a generic Concerta, and does not include any other new generics they may be working on.
Just speculating with my limited math skills, lol, but if anyone wants to get out their calculator and correct my math or expand on expectations, PLEASE have at it.
Adderall IR...........$389.8 M
Adderall XR...........$1.56 B
Dantrolene............$6.3 M
Isradipine............$5.5 M
Loxapine..............$5 M
Phendimetrazine.......$4.5 M
Trimipramine..........$2 M
Naltrexone............$16 M
Phentermine Capsules..$7.5 M
Phentermine Tablets...$40 M
Vigabatrin............$233.7 M
Methotrexate..........$63.4M
Current on the market total = $2.334B
Many have not reached full market potential but based on the totals, Elite has approximately 2.5% of the total market for all the above based on FY2024 revenue.
Expect trending UP to over 5% for these in next couple of years = $116.7M
Percocet..............$500 M
Norco.................$477 M
Methadone.............$30 M
Launching SOON market total = $1.007B
Apply the same 2.5% and it will bring Elite an additional $25M in revenue.
Expect trending UP to over 5% for these in next several years = $50.4M in revenue.
Vyvanse...............$5.10 B
Expected approval in November 2024 at the latest and Elite say launch to take priority and as quick as possible.
Apply the same 2.5% and it will bring Elite an additional $127.5M in revenue.
OxyContin.............$720 M
Pending approval and resolving patent case.
Apply the same 2.5% and it will bring Elite an additional $18M in revenue.
So, just estimating revenue growth in FY2025 and following trend same increase from last year you will get $78M for current drugs and then add in those launching and it should be between $90M to $100M.
Now go out two years with currently manufactured drug sales increasing, launched drugs taking off, Vyvanse and Oxy in production and Elite could be generating over $200 MILLION in revenue!!! The above does not include Israel/Dexcel's sales of Adderall, does not include other possibilities with Dexcel, does not include Elite's current development of a generic Concerta, and does not include any other new generics they may be working on.
Just speculating with my limited math skills, lol, but if anyone wants to get out their calculator and correct my math or expand on expectations, PLEASE have at it.
Recent ELTP News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 12:05:23 PM
- Elite Pharmaceuticals Announces Commercial Launch of Methadone Hydrochloride Tablets • Newsfile • 04/02/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/17/2026 10:10:32 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2026 (three months ended December 31, 2025) and Provides Conference Call Information • Newsfile • 02/17/2026 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:06:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/11/2026 09:35:26 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2026 Financial Results on February 18, 2026 • Newsfile • 02/11/2026 09:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2026 09:35:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2025 10:10:23 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2026 Ended September 30, 2025 and Provides Conference Call Information • Newsfile • 11/14/2025 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:11:38 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 11/12/2025 10:19:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2025 12:15:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/10/2025 12:15:46 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2026 Financial Results on November 17, 2025 • Newsfile • 11/10/2025 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/26/2025 09:17:39 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/22/2025 01:39:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2025 08:37:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2025 08:35:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/25/2025 10:05:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/10/2025 08:17:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/08/2025 08:15:11 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/08/2025 02:58:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/30/2025 08:27:51 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 06/30/2025 08:05:59 PM
